Safety and efficacy of long-term treatment of secondary hyperparathyroidism by low-dose intravenous calcitriol

S. M. Sprague, Sharon Moe

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

To assess the safety and efficacy of low-dose intravenous (IV) calcitriol therapy for the treatment of secondary hyperparathyroidism, 21 hemodialysis patients with amino-terminal parathyroid hormone (N-PTH) levels greater than 4 times normal were treated for 12 to 24 months in a prospective trial. The initial dose was 0.50 μg, which was titrated every 3 months thereafter, as dictated by predialysis calcium, phosphorus, and N-PTH concentration. Dialysate calcium concentration was 1.5 mmol/L. Low-dose IV calcitriol decreased the N-PTH concentration to 48 ± 6% and 29 ± 5% of baseline following 12 and 24 months of therapy, respectively. The maximum dose of calcitriol was 0.92 ± 0.11 μg (0.50 to 2.25 μg). After 12 months of therapy, serum calcium increased from 2.22 ± 0.04 to 2.41 ± 0.03 mmol/L (8.9 ± 0.2 to 9.7 ± 0.1 mg/dL) without change thereafter. Baseline serum phosphorus was 1.44 ± 0.09 mmol/L (4.5 ± 0.3 mg/dL), and was unaltered by calcitriol therapy. Control of serum phosphorus was achieved with calcium- containing phosphate binders, except in three patients who were subsequently withdrawn from the study after 12 months because of persistent hyperphosphatemia due to noncompliance. We conclude that long-term, low-dose IV calcitriol is a safe and effective therapy for most hemodialysis patients with secondary hyperparathyroidism. In contrast to conventional dosing regimens, low-dose IV therapy does not necessitate the use of aluminum- containing phosphate binders and/or a low-calcium dialysate bath.

Original languageEnglish (US)
Pages (from-to)532-539
Number of pages8
JournalAmerican Journal of Kidney Diseases
Volume19
Issue number6
StatePublished - 1992
Externally publishedYes

Fingerprint

Secondary Hyperparathyroidism
Calcitriol
Safety
Phosphorus
Calcium
Dialysis Solutions
Therapeutics
Renal Dialysis
Serum
Hyperphosphatemia
Baths

ASJC Scopus subject areas

  • Nephrology

Cite this

Safety and efficacy of long-term treatment of secondary hyperparathyroidism by low-dose intravenous calcitriol. / Sprague, S. M.; Moe, Sharon.

In: American Journal of Kidney Diseases, Vol. 19, No. 6, 1992, p. 532-539.

Research output: Contribution to journalArticle

@article{5f3dd2c4de2546349499e4af0b969061,
title = "Safety and efficacy of long-term treatment of secondary hyperparathyroidism by low-dose intravenous calcitriol",
abstract = "To assess the safety and efficacy of low-dose intravenous (IV) calcitriol therapy for the treatment of secondary hyperparathyroidism, 21 hemodialysis patients with amino-terminal parathyroid hormone (N-PTH) levels greater than 4 times normal were treated for 12 to 24 months in a prospective trial. The initial dose was 0.50 μg, which was titrated every 3 months thereafter, as dictated by predialysis calcium, phosphorus, and N-PTH concentration. Dialysate calcium concentration was 1.5 mmol/L. Low-dose IV calcitriol decreased the N-PTH concentration to 48 ± 6{\%} and 29 ± 5{\%} of baseline following 12 and 24 months of therapy, respectively. The maximum dose of calcitriol was 0.92 ± 0.11 μg (0.50 to 2.25 μg). After 12 months of therapy, serum calcium increased from 2.22 ± 0.04 to 2.41 ± 0.03 mmol/L (8.9 ± 0.2 to 9.7 ± 0.1 mg/dL) without change thereafter. Baseline serum phosphorus was 1.44 ± 0.09 mmol/L (4.5 ± 0.3 mg/dL), and was unaltered by calcitriol therapy. Control of serum phosphorus was achieved with calcium- containing phosphate binders, except in three patients who were subsequently withdrawn from the study after 12 months because of persistent hyperphosphatemia due to noncompliance. We conclude that long-term, low-dose IV calcitriol is a safe and effective therapy for most hemodialysis patients with secondary hyperparathyroidism. In contrast to conventional dosing regimens, low-dose IV therapy does not necessitate the use of aluminum- containing phosphate binders and/or a low-calcium dialysate bath.",
author = "Sprague, {S. M.} and Sharon Moe",
year = "1992",
language = "English (US)",
volume = "19",
pages = "532--539",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Safety and efficacy of long-term treatment of secondary hyperparathyroidism by low-dose intravenous calcitriol

AU - Sprague, S. M.

AU - Moe, Sharon

PY - 1992

Y1 - 1992

N2 - To assess the safety and efficacy of low-dose intravenous (IV) calcitriol therapy for the treatment of secondary hyperparathyroidism, 21 hemodialysis patients with amino-terminal parathyroid hormone (N-PTH) levels greater than 4 times normal were treated for 12 to 24 months in a prospective trial. The initial dose was 0.50 μg, which was titrated every 3 months thereafter, as dictated by predialysis calcium, phosphorus, and N-PTH concentration. Dialysate calcium concentration was 1.5 mmol/L. Low-dose IV calcitriol decreased the N-PTH concentration to 48 ± 6% and 29 ± 5% of baseline following 12 and 24 months of therapy, respectively. The maximum dose of calcitriol was 0.92 ± 0.11 μg (0.50 to 2.25 μg). After 12 months of therapy, serum calcium increased from 2.22 ± 0.04 to 2.41 ± 0.03 mmol/L (8.9 ± 0.2 to 9.7 ± 0.1 mg/dL) without change thereafter. Baseline serum phosphorus was 1.44 ± 0.09 mmol/L (4.5 ± 0.3 mg/dL), and was unaltered by calcitriol therapy. Control of serum phosphorus was achieved with calcium- containing phosphate binders, except in three patients who were subsequently withdrawn from the study after 12 months because of persistent hyperphosphatemia due to noncompliance. We conclude that long-term, low-dose IV calcitriol is a safe and effective therapy for most hemodialysis patients with secondary hyperparathyroidism. In contrast to conventional dosing regimens, low-dose IV therapy does not necessitate the use of aluminum- containing phosphate binders and/or a low-calcium dialysate bath.

AB - To assess the safety and efficacy of low-dose intravenous (IV) calcitriol therapy for the treatment of secondary hyperparathyroidism, 21 hemodialysis patients with amino-terminal parathyroid hormone (N-PTH) levels greater than 4 times normal were treated for 12 to 24 months in a prospective trial. The initial dose was 0.50 μg, which was titrated every 3 months thereafter, as dictated by predialysis calcium, phosphorus, and N-PTH concentration. Dialysate calcium concentration was 1.5 mmol/L. Low-dose IV calcitriol decreased the N-PTH concentration to 48 ± 6% and 29 ± 5% of baseline following 12 and 24 months of therapy, respectively. The maximum dose of calcitriol was 0.92 ± 0.11 μg (0.50 to 2.25 μg). After 12 months of therapy, serum calcium increased from 2.22 ± 0.04 to 2.41 ± 0.03 mmol/L (8.9 ± 0.2 to 9.7 ± 0.1 mg/dL) without change thereafter. Baseline serum phosphorus was 1.44 ± 0.09 mmol/L (4.5 ± 0.3 mg/dL), and was unaltered by calcitriol therapy. Control of serum phosphorus was achieved with calcium- containing phosphate binders, except in three patients who were subsequently withdrawn from the study after 12 months because of persistent hyperphosphatemia due to noncompliance. We conclude that long-term, low-dose IV calcitriol is a safe and effective therapy for most hemodialysis patients with secondary hyperparathyroidism. In contrast to conventional dosing regimens, low-dose IV therapy does not necessitate the use of aluminum- containing phosphate binders and/or a low-calcium dialysate bath.

UR - http://www.scopus.com/inward/record.url?scp=0026710166&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026710166&partnerID=8YFLogxK

M3 - Article

VL - 19

SP - 532

EP - 539

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

SN - 0272-6386

IS - 6

ER -